Erythroid transcription factor (GATA-1) (GATA1)

Erythroid transcription factor (GATA-1) is a zinc-finger DNA-binding protein and a master regulator of hematopoiesis, specifically driving the maturation of erythroid, megakaryocytic, eosinophilic, and mast cell lineages [1, 24]. It is a founding member of the GATA family and binds to the consensus (A/T)GATA(A/G) DNA motif to activate or repress a broad array of target genes involved in hemoglobin synthesis, cell cycle control, and anti-apoptotic signaling [6, 16]. GATA-1 is essential for terminal differentiation, participating in the 'GATA switch' where it replaces GATA-2 at regulatory loci to promote maturation [24]. Clinical mutations in the GATA1 gene are well-established drivers of various hematological disorders, including X-linked dyserythropoietic anemia, Diamond-Blackfan anemia, and acute megakaryoblastic leukemia (AMKL) in Down syndrome patients [3, 7]. While traditionally considered an 'undruggable' target due to its transcription factor nature, emerging research identifies small molecules like fenretinide that can induce GATA-1 degradation, offering potential therapeutic opportunities for M6 and M7 AML [11]. However, therapeutic targeting of GATA-1 presents significant safety challenges, as its systemic inhibition risks severe anemia and thrombocytopenia by disrupting essential normal hematopoiesis [6, 14].

Other names

GF-1NFE1NF-E1ERYF1GATA-binding factor 1GF1XLANPXLTDAXLTT

Pharmacological modulation of GATA-1 involves small molecule-induced protein degradation, such as with fenretinide, or functional inhibition through protein-protein interactions, as seen with activated glucocorticoid receptors interfering with GATA-1 DNA binding and transcriptional activity [11, 12].